三种血液系统恶性肿瘤的共存与首次记录的突变有关:“一列火车可以隐藏另一列”°,甚至更多!

IF 3.2 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Tamim Alsuliman , Souhila Ikhlef , Nicolas Stocker , Fazia Kaoui , Laure Ricard , Malek Aoudjhane , Mohamad Mohty , Zora Marjanovic
{"title":"三种血液系统恶性肿瘤的共存与首次记录的突变有关:“一列火车可以隐藏另一列”°,甚至更多!","authors":"Tamim Alsuliman ,&nbsp;Souhila Ikhlef ,&nbsp;Nicolas Stocker ,&nbsp;Fazia Kaoui ,&nbsp;Laure Ricard ,&nbsp;Malek Aoudjhane ,&nbsp;Mohamad Mohty ,&nbsp;Zora Marjanovic","doi":"10.1016/j.retram.2023.103403","DOIUrl":null,"url":null,"abstract":"<div><p>Coexisting malignancies is not only an uncommon event but, it can also represent a medical challenge. Its complexity relies on the difficulty of management and the need for personalized and prioritized therapeutic approaches, on the one hand, and in the potential misdiagnosis of recurrence or even a de novo disease, on the other.</p><p>Here, we present a case of a 69-year-old patient, who was initially diagnosed with a chronic myelomonocytic leukemia (CMML), followed by monoclonal gammopathy<span> of uncertain significance (MGUS). Few years later, the patient developed Hodgkin's lymphoma (HL), and a new mutation, previously undocumented in the medical literature, was also detected.</span></p><p><span>As a conclusion, we can say that the decision must be taken with caution and must be based on two major factors: 1- The rapid evolution of malignancies: give priority to treating the most rapid/life-threatening disease. 2- Prioritize the treatment of symptomatic disease and/or that which may most improve patients’ </span>quality of life.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103403"},"PeriodicalIF":3.2000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Coexistence of three hematological malignancies in association with a first time documented mutation: “One train can hide another”°, and even more!\",\"authors\":\"Tamim Alsuliman ,&nbsp;Souhila Ikhlef ,&nbsp;Nicolas Stocker ,&nbsp;Fazia Kaoui ,&nbsp;Laure Ricard ,&nbsp;Malek Aoudjhane ,&nbsp;Mohamad Mohty ,&nbsp;Zora Marjanovic\",\"doi\":\"10.1016/j.retram.2023.103403\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Coexisting malignancies is not only an uncommon event but, it can also represent a medical challenge. Its complexity relies on the difficulty of management and the need for personalized and prioritized therapeutic approaches, on the one hand, and in the potential misdiagnosis of recurrence or even a de novo disease, on the other.</p><p>Here, we present a case of a 69-year-old patient, who was initially diagnosed with a chronic myelomonocytic leukemia (CMML), followed by monoclonal gammopathy<span> of uncertain significance (MGUS). Few years later, the patient developed Hodgkin's lymphoma (HL), and a new mutation, previously undocumented in the medical literature, was also detected.</span></p><p><span>As a conclusion, we can say that the decision must be taken with caution and must be based on two major factors: 1- The rapid evolution of malignancies: give priority to treating the most rapid/life-threatening disease. 2- Prioritize the treatment of symptomatic disease and/or that which may most improve patients’ </span>quality of life.</p></div>\",\"PeriodicalId\":54260,\"journal\":{\"name\":\"Current Research in Translational Medicine\",\"volume\":\"71 3\",\"pages\":\"Article 103403\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Research in Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2452318623000272\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318623000272","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

恶性肿瘤共存不仅是一种罕见的事件,而且也可能是一种医学挑战。它的复杂性一方面取决于管理的困难和对个性化和优先治疗方法的需求,另一方面也取决于复发甚至新发疾病的潜在误诊。在这里,我们介绍了一例69岁的患者,他最初被诊断为慢性粒单核细胞白血病(CMML),随后是意义不确定的单克隆gammopathy(MGUS)。几年后,患者患上了霍奇金淋巴瘤(HL),并检测到了一种新的突变,以前在医学文献中没有记录。总之,我们可以说,必须谨慎做出决定,并且必须基于两个主要因素:1-恶性肿瘤的快速演变:优先治疗最快速/危及生命的疾病。2-优先治疗有症状的疾病和/或最能改善患者生活质量的疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Coexistence of three hematological malignancies in association with a first time documented mutation: “One train can hide another”°, and even more!

Coexisting malignancies is not only an uncommon event but, it can also represent a medical challenge. Its complexity relies on the difficulty of management and the need for personalized and prioritized therapeutic approaches, on the one hand, and in the potential misdiagnosis of recurrence or even a de novo disease, on the other.

Here, we present a case of a 69-year-old patient, who was initially diagnosed with a chronic myelomonocytic leukemia (CMML), followed by monoclonal gammopathy of uncertain significance (MGUS). Few years later, the patient developed Hodgkin's lymphoma (HL), and a new mutation, previously undocumented in the medical literature, was also detected.

As a conclusion, we can say that the decision must be taken with caution and must be based on two major factors: 1- The rapid evolution of malignancies: give priority to treating the most rapid/life-threatening disease. 2- Prioritize the treatment of symptomatic disease and/or that which may most improve patients’ quality of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Research in Translational Medicine
Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
7.00
自引率
4.90%
发文量
51
审稿时长
45 days
期刊介绍: Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信